Key Highlights
Eli Lilly announced on Thursday that its investigational compound Retatrutide successfully met its primary endpoint in the first late-stage diabetes study, demonstrating significant blood sugar control and weight loss effects for patients with type 2 diabetes.
The study lasted 40 weeks and recruited type 2 diabetes patients who were only managing their condition through lifestyle adjustments. Participants had baseline HbA1c measurements ranging from 7% to 9.5% at the start of the trial.
The experimental treatment showed an average reduction in HbA1c levels between 1.7% and 2% across various dosage levels, far exceeding the control group's reduction of 0.8%. This result met the study's primary efficacy endpoint.
In terms of weight change, participants receiving the highest dose experienced an average weight loss of 16.8% upon completion of treatment. When considering all participants, including those who dropped out, the average weight loss was 15.3%.
Scotiabank analyst Louise Chen described these findings as “the highest level of weight loss we have seen so far in a patient population that has been difficult to achieve significant weight loss.”
Analysts at JPMorgan took a more cautious stance, noting that the drug's efficacy improvements need to be weighed against its higher incidence of adverse events compared to Lilly's diabetes drug Mounjaro.
Mechanism Analysis
This treatment strategy involves simultaneously targeting three biological pathways to reduce appetite, regulate glucose metabolism, and enhance metabolic energy expenditure.
Adverse reactions were primarily gastrointestinal in nature. Approximately 26.5% of participants receiving the highest dose reported nausea, 22.8% experienced diarrhea, and 17.6% encountered vomiting. The proportion of patients who discontinued treatment due to adverse reactions was 5%, which Lilly considers relatively low.
A small number of participants reported sensory abnormalities, specifically discomfort related to nerve issues.
Regulatory Progress and Market Position
Lilly has not yet submitted a regulatory application for Retatrutide for obesity or diabetes indications. Thursday's announcement marks the second Phase 3 clinical data set released for this compound.
The pharmaceutical company expects to report results from seven more Phase 3 clinical trials in 2025, covering different patient populations.
Meanwhile, Lilly is preparing to launch its oral obesity drug orforglipron in the second quarter of this year, pending FDA approval.
At the same time, Novo Nordisk is actively advancing its competitive progress. In March 2025, Novo obtained a license for a triple receptor compound from United Laboratories International, valued at up to $2 billion, although this candidate is still in early development and will require several more years.